Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00357708
Recruitment Status : Completed
First Posted : July 27, 2006
Last Update Posted : January 7, 2013
Information provided by (Responsible Party):
National Cancer Institute (NCI)